Stability of Cyclophosphamide and Mesna Admixtures in Polyethylene Infusion Bags

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1789-1792

  Menard, Cedric ^a   Bourguignon, Celine ^a   Schlatter, Joël ^a,b   Vermerie, Norbert ^a  

^a HÔPITAL JEAN VERDIER   (France)

^b NONE   (France)

Author keywords

Admixtures; Cyclophosphamide; Mesna; Stability

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; POLYETHYLENE;

ARTICLE; DRUG INFUSION; DRUG STABILITY; DRUG STORAGE; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; LOW TEMPERATURE; PH MEASUREMENT; PRIORITY JOURNAL; ROOM TEMPERATURE;

CYCLOPHOSPHAMIDE; DRUG STABILITY; INFUSION PUMPS; MESNA; PHARMACEUTICAL SOLUTIONS; POLYETHYLENE;

EID: 0344412970     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D200     Document Type: Article

References (17)

1. French Cooperative Group on Chronic Lymphocytic Leukaemia. Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br J Haematol 1989;73:334-40.
2. Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990;17:716-35.
3. Coiffier B, Bosly A, Caligaris-Cappio F, Gisselbrecht C, Patte C, Schaadt M, et al. European School of Oncology: management of non-Hodgkin's lymphomas: conclusions of the European School of Oncology Meeting, 1986. Eur J Cancer Clin Oncol 1987;23:1691-5.
4. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
5. Brock N. The oxazaphosphorines. Cancer Treat Rev 1983;10(suppl A):3-15.
6. Kushner BH, Cheung NK. Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet 1990;28:253-4.
7. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979;29:659-61.
8. Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol 1981;17:1155-63.
9. Burkert H. Clinical overview of mesna. Cancer Treat Rev 1983;10(suppl A):175-81.
10. Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol 1981;100:311-20.
11. Ehrlich RM, Freedman A, Goldsobel AB, Stiehm ER. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. J Urol 1984;131:960-2.
12. American Society of Clinical Oncology. Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
13. Sievers TD, Lagan MA, Bartel SB, Rasco C, Blanding PJ. Variation in administration of cyclophosphamide and mesna in the treatment of childhood malignancies. J Pediatr Oncol Nurs 2001;18:37-45.
14. Beijnen JH, van Gijn R, Challa EE, Kaijser GP, Underberg WJ. Chemical stability of two sterile parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids. J Parenter Sci Technol 1992;46:111-6.
15. Allwood M, Stanley A, Wright P. The cytotoxics handbook. 4th ed. Oxford: Radcliffe Medical Press, 2002.
16. Physician's desk reference. 55th ed. Montvale, NJ: Medical Economics, 2001.
17. Gilard V, Martino R, Malet-Martino MC, Kutscher B, Muller A, Niemeyer U, et al. Chemical and biological evaluation of hydrolysis products of cyclophosphamide. J Med Chem 1994;37:3986-93.